- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EXACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | EXACT Therapeutics AS: Notice of extraordinary general meeting | 2 | Oslo Børs | ||
| Fr | EXACT Therapeutics AS: Warrants exercise | - | Oslo Børs | ||
| 12.02. | EXACT Therapeutics AS: Financial calendar | - | Oslo Børs | ||
| 11.02. | EXACT Therapeutics AS: EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program | 2 | Oslo Børs | ||
| 06.02. | EXACT Therapeutics AS: EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program | 1 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Correction of final warrants exercise date | 2 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders | 2 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB | 2 | Oslo Børs | ||
| 27.01. | EXACT Therapeutics AS: EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants | 1 | Oslo Børs | ||
| 08.01. | EXACT Therapeutics AS: EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium | - | Oslo Børs | ||
| 25.11.25 | EXACT Therapeutics AS: EXACT Therapeutics to present company update | 1 | Oslo Børs | ||
| 24.11.25 | EXACT Therapeutics AS: New option program and receipt of share options by primary insiders | 4 | Oslo Børs | ||
| 25.09.25 | EXACT Therapeutics AS: EXACT Therapeutics first half 2025 interim results | 3 | Oslo Børs | ||
| 18.09.25 | EXACT Therapeutics AS: EXACT Therapeutics' Phase 2 trial to be presented at the 2025 AACR Special Conference | 1 | Oslo Børs | ||
| 09.09.25 | EXACT Therapeutics AS: EXACT Therapeutic's Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference | 1 | Oslo Børs | ||
| 24.06.25 | Exact Therapeutics AS: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer | 238 | GlobeNewswire (Europe) | OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.... ► Artikel lesen | |
| 20.05.25 | Exact Therapeutics AS: EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer | 363 | GlobeNewswire (Europe) | These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapyIn the patients who had a response to chemotherapy, ACT-treated... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | 0,00 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| TREVI THERAPEUTICS | 12,570 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | 0,00 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| PRAXIS PRECISION MEDICINES | 330,19 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 32,520 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,680 | 0,00 % | Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update | ||
| KINIKSA PHARMACEUTICALS | 46,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen |
Das Unternehmen EXACT THERAPEUTICS AS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,121 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXACT THERAPEUTICS AS finden Sie auf Wallstreet Online.